| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/24/2003 | WO2003032899A2 Methods and materials for targeting and affecting selected cells |
| 04/24/2003 | WO2003032898A2 Modified human thymic stromal lymphopoietin |
| 04/24/2003 | WO2003032814A2 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 04/24/2003 | WO2003032813A2 Methods for the treatment of carcinoma |
| 04/24/2003 | WO2003007915A3 Compositions for treatment of head and neck cancers, and methods of making and using the same |
| 04/24/2003 | WO2003005964A3 Recombinant vsv for the treatment of tumor cells |
| 04/24/2003 | WO2003004631A3 USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS. |
| 04/24/2003 | WO2003004049A3 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 04/24/2003 | WO2002098907A3 Cation conducting gabaa receptors and their use |
| 04/24/2003 | WO2002098850A3 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 04/24/2003 | WO2002085848A3 Synthesis of pancratistatin prodrugs |
| 04/24/2003 | WO2002079429A3 Anti-muc-1 single chain antibodies for tumor targeting |
| 04/24/2003 | WO2002079219A3 Anti-proliferative 6-o-acyl-beta-d-glucosyl-beta-sitosterol compounds |
| 04/24/2003 | WO2002079147A3 Inhibitors of prenyl-protein transferase |
| 04/24/2003 | WO2002076509A3 Preparation for the prophylaxis of restenosis |
| 04/24/2003 | WO2002074959A3 Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1 |
| 04/24/2003 | WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 04/24/2003 | WO2002066626A3 Regulation of human mut/nudix nucleoside triphosphate pyrophosphohydrolase |
| 04/24/2003 | WO2002066018A3 Transdermal therapeutic system containing testosterone and method for the production thereof |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002060436A8 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 04/24/2003 | WO2002058690A3 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| 04/24/2003 | WO2002057483A3 Method of identifying modulators of nogo-functions |
| 04/24/2003 | WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | WO2002050120A3 High affinity antibodies |
| 04/24/2003 | WO2002047710A3 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer |
| 04/24/2003 | WO2002046383A3 Protein modification and maintenance molecules |
| 04/24/2003 | WO2002045707A3 Polynucleotide intercalator interceptors and inhibitors |
| 04/24/2003 | WO2002043741A3 Methylenetetrahydrofolate reductase inhibitors and use thereof |
| 04/24/2003 | WO2002031498A3 Protecting therapeutic compositions from host-mediated inactivation |
| 04/24/2003 | WO2002026825A3 G-protein coupled receptors |
| 04/24/2003 | WO2002018585A8 Packaging of positive-strand rna virus replicon particles |
| 04/24/2003 | WO2002017952A3 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| 04/24/2003 | WO2002016615A3 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 04/24/2003 | WO2002014554A3 The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| 04/24/2003 | WO2002012447A3 Isolation and use of solid tumor stem cells |
| 04/24/2003 | US20030078438 N-heterocyclicamide compounds; used as anticoagulant agent |
| 04/24/2003 | US20030078432 Novel benzotriazoles anti-inflammatory compounds |
| 04/24/2003 | US20030078426 Thiazolidine or oxazolidine compounds useful for preventing or therapeutical agents for various diseases such as diabetes and hyperlipemia |
| 04/24/2003 | US20030078405 47 human secreted proteins |
| 04/24/2003 | US20030078391 Nucleotide sequences coding polypeptide for use in treatment of periodontal disease |
| 04/24/2003 | US20030078299 Anti-cancer nitro- and thia-fatty acids |
| 04/24/2003 | US20030078289 Indole carboxylic acids as thyroid receptor ligands |
| 04/24/2003 | US20030078288 Indole derivatives |
| 04/24/2003 | US20030078281 Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
| 04/24/2003 | US20030078280 Macroheterocylic compounds useful as kinase inhibitors |
| 04/24/2003 | US20030078276 Matrix metalloproteinase inhibitors |
| 04/24/2003 | US20030078275 For therapy of cancer, diabetes and Alzheimer's disease |
| 04/24/2003 | US20030078270 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| 04/24/2003 | US20030078265 Inhibitors of nitric oxide synthase (nos) |
| 04/24/2003 | US20030078263 Nonnucleotide compounds which interact with specific structures of dna; anticancer agents |
| 04/24/2003 | US20030078257 Methods of treating tumors |
| 04/24/2003 | US20030078254 Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 04/24/2003 | US20030078252 Used to treat abnormal cell growth and central nervous system disorders |
| 04/24/2003 | US20030078239 Ketone compounds and compositions for cholesterol management and related uses |
| 04/24/2003 | US20030078232 A stimulants for bone marrow cell proliferation, countering the toxic side effect of drugs, in particular chemotherapeutic drugs, such as leukopenia and neutropenia |
| 04/24/2003 | US20030078222 Human receptor tyrosine kinase |
| 04/24/2003 | US20030078214 Phytooestrogen selected from genistein, daidzein; for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia |
| 04/24/2003 | US20030078166 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| 04/24/2003 | US20030077819 Oncolytic virus therapy |
| 04/24/2003 | US20030077802 Human PRL1 phosphatase |
| 04/24/2003 | US20030077735 Novel human Kchannel and therapeutic applications thereof |
| 04/24/2003 | US20030077734 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 04/24/2003 | US20030077708 Antigen presenting system and methods for activation of T-cells |
| 04/24/2003 | US20030077694 Nucleotide sequences coding polypeptide for use in the treatment of inflammatory disorders |
| 04/24/2003 | US20030077683 IKK-alpha proteins, nucleic acids and methods |
| 04/24/2003 | US20030077676 Anti-MUC-1 single chain antibodies for tumor targeting |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077624 Diagnosing cancer in mammals; obtain sample cells, monitor expression of collapsin protein, amplified concentration of collapsin indicates cancer |
| 04/24/2003 | US20030077568 Screening drugs; obtain cell with preferential phenotypic profile, incubate with drug, monitor effect on cells |
| 04/24/2003 | US20030077565 Preservation of corneal graft in vitro; obtain graft, incubate with antisense oligonucleotides in solution, monitor viability of graft tissue |
| 04/24/2003 | US20030077343 Angiogenesis inhibitors; antiinflammatory agents; topical applying to skins |
| 04/24/2003 | US20030077327 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | US20030077318 Activation lymphocytes; therapy for aids, cancer; immobilization on solid support |
| 04/24/2003 | US20030077305 Administering to a mammal a formualtion comprising cationic lipids/DNA complex, allowing the complex to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time such that the complex enters the target cells |
| 04/24/2003 | US20030077295 Dendritic-platinate drug delivery system |
| 04/24/2003 | US20030077285 Methods of diagnosis and treatment by binding p75/airm1 |
| 04/24/2003 | US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells |
| 04/24/2003 | US20030077277 Human antibodies that have MN binding and cell adhesion-neutralizing activity |
| 04/24/2003 | US20030077276 Expression vectors constructed by inserting antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing rat onoclonal antibody reacting with ganglioside gm2 |
| 04/24/2003 | US20030077275 Chimeric antibody specific to human CD4 which comprises the variable heavy and light chain sequences of an Old World monkey monoclonal antibody produced against human CD4 and human constant heavy and light domain sequences |
| 04/24/2003 | US20030077271 Use of coagulation factor VII-activating protease for the prophylaxis and therapy of vasoproliferative disorders |
| 04/24/2003 | US20030077257 Administering a dosage of alive larva of nematodes; immunogens treating cancer of the first and second stages, and AIDS-infections |
| 04/24/2003 | US20030077252 Vaccination against plaque forming diseases; inhibiting aggregation of amyloid in mammal and/or to cause disaggregation of amyloid; treating brain disorder, Alzheimer's disease |
| 04/24/2003 | US20030077250 Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene |
| 04/24/2003 | US20030077249 DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling polypeptides; drug delivery system for treating cancer |
| 04/24/2003 | US20030077248 Treating cancer with a culture product from a non-naturally occurring antigen-presenting cell; polyclonal antibodies expression |
| 04/24/2003 | US20030077247 Chemokines as adjuvants of immune response |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030077243 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/24/2003 | US20030077228 Polar solvent 30-99.69%, active compound 0.001-60%, and f lavoring agent 0.1-10%; propellant free |
| 04/24/2003 | US20030077227 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/24/2003 | US20030075172 Method and apparatus for dispensing inhalator medicament |
| 04/24/2003 | CA2722197A1 Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| 04/24/2003 | CA2684419A1 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity |
| 04/24/2003 | CA2466889A1 Use of the adenoviral e2 late promoter |
| 04/24/2003 | CA2463996A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | CA2463994A1 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications |
| 04/24/2003 | CA2463943A1 Human antibodies that have mn binding and cell adhesion-neutralizing activity |